InsidersTradesSigma
Follow the 차바이오텍 share price and the full insider trade history of the company, a listed issuer based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 차바이오텍 has recorded 95 reports. Market capitalisation: €785.6bn. The latest transaction was filed on 22 May 2026 (Purchase). Among the most active insiders: 차광렬. The full history is free.
94
Insider Decl.
n/a
Thresholds
n/a
13 ops.
Buy Volume
€846,999
11 ops.
Sell Volume
3Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,994 of 29,062 companies
18.5
score / 100
Value10
Quality27
FCF yld-29%
Earn yld-14%
EV/EBITDA·
ROE-1.8%
Gross mgn29%
Net mgn-8.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 22 May 2026
Declarations95 total
Other
25 of 95 declarations
Acerca de 차바이오텍
차바이오텍 es una empresa especializada en el sector de la salud y farmacéutico, que cotiza en el mercado XKRX. Se centra en el desarrollo de terapias innovadoras y soluciones biofarmacéuticas.